We are a development stage company that was established to focus on the research and development of novel all-natural drugs for a better quality of life by using the best of traditional medicines from the Amazon region of South America and from nature. Our goal is to be a world leader and contributor in the treatment of HIV naturally through the use of immune-based therapies. An immune-based therapy is defined as any treatment geared toward reestablishing proper functioning of the immune system or directly helping the immune system to fight a virus, i.e. HIV/AIDS. Our executive offices currently consist of shared office space located at 43 West 33rd Street, Suite 405, New York, NY 10001 and telephone number (212) 947-3362, and shared offices at Ofer Building, 5 Nahum Hefzadi Street, Jerusalem, Israel 95484. We maintain a website at www.amazonbiotech.com.
TeraView was spun-out of Toshiba Research Europe in April 2001 by its co-founders, Sir Michael Pepper (CSO) and Dr Don Arnone (CEO), to exploit the intellectual property and expertise developed in sourcing and detecting terahertz (1 THz= 33.3cm -1) radiation, using innovative semiconductor technologies. Leading industry proponents of the technology sit on our Advisory Board, and TeraView maintains close links with the Cavendish Laboratory at the University of Cambridge, where modern terahertz technology was pioneered in conjunction with the team at TeraView, and where Professor Pepper, has held the position of Professor of Physics since 1987. Uniquely, the Company has a wealth of experience in both the technology to generate, detect and manipulate terahertz light, as well as an extraordinary breadth and depth of knowledge in applications of the technology in different markets to solve real world problems for our customers. Both of these attributes are represented in our product offering to customers, as well as an impressive intellectual property portfolio that builds considerable value for the Company. The result is our proprietary TPIÔ platform that can be configured to meet a variety of end-user needs.
http://www.imagingresearch.com
Imaging Research, a subsidiary of Amersham Biosciences, is a software and instrument developer, producing analytical imaging systems, screening systems, and bioinformatics software for life science research and pharmaceutical drug discovery. Imaging Research markets its products and services directly and through selected distributors worldwide.
Interpharm currently develops, manufactures and distributes generic prescription strength and over-the-counter pharmaceutical products. Interpharm will continue to focus on growing organically through internal product development and leveraging its strength in efficient and cost effective manufacturing. In addition, Interpharm will also continue to seek consummation of mutually beneficial strategic alliances and collaborations.
Phoqus Pharmaceuticals is a speciality pharmaceutical company that develops differentiated products for use in high-value, specialist indications. It seeks to accelerate the rate and lower the risk of new drug development by applying its novel re-formulation expertise and drug delivery technologies to finding new indications for known, approved drugs. This avoids the high failure rate typically associated with new chemical entities (NCEs), which often founder due to safety issues encountered early in development. The company's lead product is ChronocortTM for the treatment of patients with cortisol deficiency due to diseases such as congenital adrenal hyperplasia and Addison's Disease. It is differentiated from existing therapies because it is designed to release the steroid in a pattern that mirrors a healthy subject. At present ChronocortTM is scheduled to reach the market in 2009/10, subject to the successful completion of the clinical trials and regulatory approval. Phoqus Pharmaceuticals aims to in-license product development opportunities from academia and university spin-out companies. By collaborating with these groups the company will access fundamental biological and clinical insights into existing drug action and apply this knowledge to develop new indications for those drugs. The company aims to capitalise on accelerated regulatory pathways such as the priority review process to further fast-track products to market.
Aspreva is focused on addressing the needs of individuals with less common diseases through the identification, development and commercialization of existing medicines for new indications. Aspreva uses a proprietary screening program to identify late stage and approved medicines that show potential for high therapeutic impact in less common diseases. We then partner with pharmaceutical and biopharmaceutical companies to acquire the rights to develop the drug in these new indications, including clinical research and regulatory approvals. Once approved, we apply a strategic and specialized approach to commercializing products for these complex therapeutic categories. Our expertise lies in the clinical, regulatory and commercial development of products for complex diseases and specialized patient populations which differs significantly from traditional pharmaceutical activities. Aspreva is a leader in this new era of pharmaceutical partnering.
Biovail Corporation is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company's therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease (including Type II diabetes). Biovail drives business growth by commercializing these products both directly through its own sales and marketing divisions and/or through strategic partners. Biovail's core competency lies in the development and large-scale manufacturing of pharmaceutical products incorporating oral drug-delivery technologies. Biovail has a broad portfolio of proprietary drug-delivery technologies that represent the foundation upon which the Company's strategy is based.
Cipla Limited is an Indian-based pharmaceutical company. The Company is focused on developing new formulations for existing and new drug substances. During the fiscal year ended March 31, 2008 (fiscal 2008), the Company launched many drugs and formulations, which includes Ritomune (ritonavir tablets), which is an antiretroviral for booster therapy in Human Immunodeficiency Virus/Aquired Immunodeficiency Syndrome (HIV/AIDS); Adlube, which is a lubricating eye ointment with white petrolatum and mineral oil for dry eye; Olmecip (olmesartan tablets), which is an angiotensin blocker for hypertension, and Ston 1 (potassium citrate and magnesium citrate solution) for urinary stones. Cipla FZE is the Company’s wholly owned subsidiary. (Source: ARS)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory